New pill could shrink uterine cancer without surgery
NCT ID NCT05634499
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This phase II trial is testing an oral drug called giredestrant in 30 people with grade 1 endometrial cancer. The goal is to see if the drug can shrink or control the cancer over 6 months. Participants take one pill daily for up to 24 cycles, and doctors monitor tumor changes and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Englewood Health/Hematology Oncology Practice of Englewood (HOPE)
Englewood, New Jersey, 07631, United States
-
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
Meldola, Emilia-Romagna, 47014, Italy
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
McGill University Health Centre - Glen Site
Montreal, Quebec, H4A 3J1, Canada
-
Minnesota Oncology Minneapolis
Minneapolis, Minnesota, 55404, United States
-
Mount Sinai Medical Center
Miami Beach, Florida, 33140, United States
-
Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice
Gliwice, 44-101, Poland
-
Swietokrzyskie Centrum Onkologii
Kielce, 25-734, Poland
-
Texas Oncology, P.A. - Fort Worth
Fort Worth, Texas, 76104, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
-
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
giredestrant (oral drug)
What this could lead to
If successful, this could offer a non-surgical, hormone-based option to control early-stage endometrial cancer.
What could go wrong
This is a small, early-phase trial with only 30 participants and no comparison group. The drug may not shrink tumors or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.